SHK Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹584 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
S H Kelkar reported muted Q3 performance with 9M FY26 revenue of Rs 1,718 crore (10% YoY) as the company navigates a challenging operating environment. Adjusted EBITDA margin stands at ~13% excluding new growth investments. The management highlighted this as the opportune moment to invest given competitor M&A restructuring creating space for mid-tier players, particularly in emerging DTC/e-commerce fragrance businesses. Key capex commitments include Rs 70-80 crore in India (12-18 months) for new Vashi facility, €2-3 million in Europe, and ~$2 million already invested in US creative center where first customer order was secured. Gross margins are at the lower end (~42-44%) with improvement expected from Q4 FY26 onwards as raw material costs normalize. Management targets 17% EBITDA margin and 14% ROC by FY29, projecting 12% revenue CAGR from FY25 base. Insurance claim of Rs 100 crore expected within 6-12 months. Key risks include elevated debt (~Rs 800 crore), compressed return ratios, delayed demand recovery in India, and foreign exchange headwinds on rupee-denominated costs.
Colored figures show movement against the previous available record.
Guidance to track
- Management reaffirmed 12% year-on-year revenue growth target from FY25 base, expecting FY27 to grow faster than 12% as new markets scale.
- Adjusted EBITDA margin expected to improve from current 13% to 17% over next two years through operating leverage and new facility stabilization.
- Return on Capital Employed projected to reach 14% by FY29 as international investments (Europe, US, UK) mature and generate cash flows after 3-year gestation.
- Fixed operating costs for new initiatives have peaked in dollar/euro terms; INR costs may fluctuate with currency but no major additions expected.
Risks flagged
- Despite management guidance that gross margins would improve in H2, Q3 margins remained at lower end (42-44%). Analyst questioned whether this represents 'new normal' or temporary situation; management acknowledged timing lag but provided no specific recovery quarter.
- Debt currently at ~Rs 800 crore with Rs 100 crore cash; analyst raised concern about debt-equity ratio deterioration and ROC pressure. Management acknowledged need to prioritize opportunities and defer some investments.
- Management expected faster demand revival post-GST changes announced earlier in FY26 but has not seen broad-based demand jump despite Diwali uptick.
- Management noted muted order flow from India business and delayed customer orders in Europe citing geopolitical factors, affecting near-term revenue acceleration.
Key quotes
- We see that the market is overconcentrated with three or four players and the business opportunity is more and more with large number of smaller clients with the direct to customer online e-commerce businesses coming over or taking over or starting over in many parts of the world.
- We have more than 25 patents in all these countries already with us. So that gives us a very strong base when we enter these markets. The first patents in the US for example are running out in 2030. So we have now only four or five years to capitalize on this patent cycle before they become public domain.
- Insurance claim is already under processing and we expect that should get settled in next 6 to 12 months. We are expecting in and around 100 crores and we don't see a risk on that the quantum may be plus or minus but I think we are pretty positive we'll get this money within 6 to 12 months.
Research modules